Strategizing ADC Use to Enhance Breast Cancer Outcomes
Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.
Related Articles
FDA Approves SIR-Sphere Y-90 in HCC
SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.
CEPHEUS Trial: Design/Baseline Characteristics
Panelists discuss how recent data support the use of quadruplet regimens—including anti-CD38 antibodies—even in older or moderately frail patients with newly diagnosed multiple myeloma, shifting…
Later R/R MM Treatment Landscape and Unmet Needs
Panelists discuss the unmet need for effective therapies in early-relapse multiple myeloma, where patients have exhausted standard treatments but do not yet qualify for bispecific…
ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma
Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.
Analyzing Emerging Therapies Across Breast Cancer Subtypes
Erika Hamilton, MD, gave an overview of evolving therapies and recent trial updates for patients across breast cancer subtypes.
FDA Grants Priority Review to TAR-200 in BCG-Unresponsive High-Risk NMIBC
Phase 2b SunRISe-1 trial findings supported the FDA to grant priority review to TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.
Nadunolimab Combo Exhibits Early Efficacy in Advanced NSCLC
Particularly strong efficacy signals were observed in patients with non-squamous non–small cell lung cancer previously treated with PD-1 inhibition.
Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC
Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.
Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
Breast Cancer | Oncology News & Insights | CancerNetwork
The breast cancer section is a comprehensive resource for clinical news and expert insights on breast cancer. Read more at CancerNetwork.